key: cord-0975275-fhcdt85e
authors: Nörz, Dominik; Frontzek, André; Eigner, Ulriach; Oestereich, Lisa; Wichmann, Dominic; Kluge, Stefan; Fischer, Nicole; Aepfelbacher, Martin; Pfefferle, Susanne; Lütgehetmann, Marc
title: Pushing beyond specifications: Evaluation of linearity and clinical performance of the cobas 6800/8800 SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations
date: 2020-09-23
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104650
sha: f40fd9b7952fce84e6906653eed09f5dd07f9ed6
doc_id: 975275
cord_uid: fhcdt85e

BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge to diagnostic laboratories. There are preliminary studies correlating qRT-PCR results from different materials to clinical outcomes, yet, comparability is limited due to the plethora of different assays used for diagnostics. In this study we evaluate clinical performance and linear range for the SARS-CoV-2 IVD (cobas6800/8800 system, a fully automated sample-to-result platform) in different clinically relevant matrix materials outside official specifications. METHODS: Assay performance was assessed in human plasma, BAL/BL and transport medium following chemical inactivation. For analytical evaluation, respective matrix materials were spiked with SARS-CoV-2 RNA in ten-fold dilution series. The efficacy of chemical inactivation by guanidine hydrochloride solution was confirmed in cell culture infectivity experiments. For correlation, a total of 289 predetermined clinical samples including respiratory swabs, plasma and lower respiratory tract specimens were subjected to the SARS-CoV-2 IVD test and results were compared. RESULTS: The SARS-CoV-2 IVD showed excellent linearity over four to six log steps depending on matrix material. Chemical inactivation resulted in a reduction in plaque forming units of at least 3.5 log steps, while having no significant impact on assay performance. Inter-run consistency from three different testing sites demonstrated excellent comparability of RT-PCR results (maximum deviation was 1.53 CT). Clinical evaluation for respiratory swabs showed very good agreement with the comparator assay (Positive agreement 95.7%, negative agreement 98.9%). CONCLUSION: The SARS-CoV-2 IVD test for the cobas6800/8800 systems offers excellent linear range and inter-run consistency for quantification of SARS-CoV-2 RNA in different matrices outside official specifications.

 Effective reduction of SARS-CoV-2 infectivity by chemical inactivation without affecting assay performance.

 SARS-CoV-2 IVD for the cobas 6800/8800 is linear over up to six log steps in different materials including human plasma.

 Minimal variance of CT values between testing sites indicates high comparability of quantification results.

Background: The ongoing SARS-CoV-2 pandemic presents a unique challenge to diagnostic laboratories. There are preliminary studies correlating qRT-PCR results from different materials to clinical outcomes, yet, comparability is limited due to the plethora of different assays used for diagnostics. In this study we evaluate clinical performance and linear range for the SARS-CoV-2 IVD (cobas6800/8800 system, a fully automated sample-to-result platform) in different clinically relevant matrix materials outside official specifications. Methods: Assay performance was assessed in human plasma, BAL/BL and transport medium following chemical inactivation. For analytical evaluation, respective matrix materials were spiked with SARS-CoV-2 RNA in ten-fold dilution series. The efficacy of chemical inactivation by guanidine hydrochloride solution was confirmed in cell culture infectivity experiments. For correlation, a total of 289 predetermined clinical samples including respiratory swabs, plasma and lower respiratory tract specimens were subjected to the SARS-CoV-2 IVD test and results were compared. Results: The SARS-CoV-2 IVD showed excellent linearity over four to six log steps depending on matrix material. Chemical inactivation resulted in a reduction in plaque forming units of at least 3.5 log steps, while having no significant impact on assay performance. Inter-run consistency from three different testing sites demonstrated excellent comparability of RT-PCR results (maximum deviation was 1.53 CT). Clinical evaluation for respiratory swabs showed very good agreement with the comparator assay (Positive agreement 95.7%, negative agreement 98.9%).

Conclusion: The SARS-CoV-2 IVD test for the cobas6800/8800 systems offers excellent linear range and inter-run consistency for quantification of SARS-CoV-2 RNA in different matrices outside official specifications.

Keywords: SARS-CoV-2; COVID-19; RT-PCR; Molecular Diagnostics; cobas 6800; quantification 2 Introduction:

The novel coronavirus SARS-CoV-2 has been subject of extensive study since its emergence in late December 2019 (1, 2) . Diagnostic RT-PCR was quickly determined as the gold standard for detecting the new pathogen in patients, in large part due to the rapid dissemination of complete virus sequences from the assumed origin of the outbreak in China and consecutive publication of specific PCR assays (3, 4) . Besides merely confirming the diagnosis, there exists evidence for a correlation between viral loads and clinical outcomes for various respiratory viruses, including Influenza and the original SARS-CoV (5, 6) . In the case of SARS-CoV-2 there has already been a flurry of publications describing viral load dynamics in different clinical specimens (7, 8) . It can be assumed that this topic will further grow in relevance in the coming months.

Reliable quantification of RT-PCR signals is highly dependent on assay specifications and reference materials (9) . In the absence of an international standard to serve as reference, quantification of SARS-CoV-2 RNA is ultimately based on a variety of different methods and standards used in the individual labs (8, 10) , resulting in inherently poor comparability and reproducibility between testing sites. However, the increasing availability of commercial SARS-CoV-2 RT-PCR kits for widely used fully automated systems offers the opportunity to generate highly consistent PCR results which can then be used for quantification. J o u r n a l P r e -p r o o f

The cobas6800 system is a fully automated sample-to-result high-throughput RT-PCR platform, capable of performing 384 tests in an 8 hour shift and requiring minimal hands-on time (11) . Until recently, laboratory developed tests (LDT) using the open mode (utility channel) had to be employed to use the system for SARS-CoV-2 testing (10). However, Roche has since received "Emergency use authorization" by the FDA for their own SARS-CoV-2 IVD assay and have made the test available commercially (12) . This provides a common ground across different testing sites for quantification of RT-PCR data, especially when taking the high inter-run consistency of the instrument into account, as previously demonstrated for other clinical targets (13) .

The aim of this study was to provide clinical evaluation of the new SARS-CoV-2 IVD assay by Roche and further validate clinical specimen types outside specifications for use in clinical studies. In this context, efficiency and linear range was to be determined in different clinical materials. Lastly, comparability of results was to be evaluated using a multicenter approach for inter-run variability.

Vero cells (ATCC CCL 81) were propagated in DMEM containing 10 % FCS, 1% Penicillin/ Streptomycin, 1 % L-Glutamine, (200 mM), 1 % Sodium pyruvate and 1 % non-essential amino acids (all Gibco/ Thermo Fisher, Waltham, USA). A SARS-CoV-2 isolate was rescued from an oropharyngeal swab as described previously (14) . For virus quantification, plaque-assays were J o u r n a l P r e -p r o o f performed as follows: A tenfold serial dilution series of the virus containing solution was incubated on Vero cells seeded in 24-well plates (500 µl per well). After adsorption at 37°C for 1h, cells were washed once with PBS and overlaid with DMEM containing 1% methylcellulose to prevent virus spreading within the supernatant. After 5 days of incubation at 37°C, cells were fixed in 4% formaldehyde (30 min at room temperature), washed once with H2O and stained with crystal violet solution. Virus titers in initial (stock) solutions were assessed by counting plaques.

In order to determine the virus inactivation capability of the Roche PCR Media Kit (≤ 40% guanidinehydrochloride in Tris-HCl), 100 µl of the SARS-CoV-2 stock solution (with an estimated 3x10 7 PFU/ml) were diluted 1:10 in either UTM or E-swab medium (modified Amies medium in Tris-HCl). 500 µl of each dilution were supplemented 1:1 with Roche PCR-Media, the remaining 500µl were supplemented 1:1 with either UTM or E-swab medium. After 30 min of incubation at room temperature, ten-fold serial dilution series of each mixture were used for plaque assays as described above.

The SARS-CoV-2 IVD dual-target test for the cobas6800/8800 system was obtained from Roche and used according to instructions issued by the manufacturer. Target-1 (ORF1ab) and Target-J o u r n a l P r e -p r o o f 2 (E gene) properties were analysed separately, though the entire assay was deemed positive as long as one Target returned a positive result. Apart from loading the ready-to-use SARS-CoV-2 IVD-test cartridges onto the device, there are no manual steps required in the assay setup.

For determining linear range in different matrix materials, an initial 1:20 dilution of cell culture supernatant containing SARS-CoV-2 (isolate HH-1) was prepared using UTM (with or without chemical inactivation) or normal human plasma (SARS-CoV-2 RNA negative) as diluent. For BAL/BL, clinical specimens previously tested PCR-negative for SARS-CoV-2 were pooled to serve as matrix material. The initial stock was used to generate tenfold dilution series, which were subjected to the SARS-CoV-2 IVD test in 8 repeats for each step.

All tested clinical samples were predetermined positive or negative in routine diagnostics using the SARS-CoV-2 UCT (Utility Channel Test) on the cobas6800 system. This method was This work was conducted in accordance with §12 of the Hamburg hospital law ( §12 HmbKHG).

The use of anonymized samples was approved by the ethics committee, Freie und Hansestadt Hamburg, PV5626.

Inter-run variability was compared between a total of four different instruments, located at 3 different testing sites. Triplicates of a solution containing diluted SARS-CoV-2 infected cell culture supernatant were prepared in a similar manner as described in section 3.4.

Concentrations of SARS-CoV-2 RNA were estimated to be within linear range of the assay.

Spiked sample sets were sent to "Labor Limbach", Heidelberg and "Labor Stein", Moenchengladbach (transported at 4°C) for analysis with the SARS-CoV-2 IVD test using their own cobas6800 instruments. Each set contained three identical UTM samples and three J o u r n a l P r e -p r o o f identical plasma samples, as well as a negative control. CT values were reported and compared. Only 11/12 measurements returned results for each set (UTM and plasma) due to a system crash and loss of material at one of the sites.

To confirm effective reduction of infectivity in clinical specimens, cell culture supernatants J o u r n a l P r e -p r o o f

For clinical validation, a set of predetermined samples was subjected to testing with the SARS-CoV-2 IVD and results were compared to the UCT. The SARS-CoV-2 IVD result was reported as 

For positive swab samples, as well as a further 53 predetermined positive plasma samples and 56 lower respiratory tract samples, CT values of the IVD test were compared to the UCT, which had previously been used to analyze these types of specimens, which are not recommended for the SARS-CoV-2 IVD. Target-2 (E gene) showed the best consistency with the reference assay, which is also targeting the viral E gene. The recently released SARS-CoV-2 IVD for the cobas6800/8800 systems made automated high-throughput testing available to a wider range of diagnostic facilities. First studies providing clinical evaluation have demonstrated good agreement with established reference assays (12, 15) . The benefits of automation for molecular diagnostics have been discussed extensively in previous studies (11, 16) . While various sample-to-result systems were already used for SARS-CoV-2 diagnostics utilizing open modes during the early weeks of the pandemic (10, 17, 18) , commercial test kits have since been released under emergency use authorization (EUA) for most automated PCR-platforms (12, 19, 20) .

The SARS-CoV-2 IVD for the cobas 6800/8800 system provides a well standardized common ground for comparable quantification results and viral load monitoring, despite nominally being only a "qualitative" test. At present, the assay is limited by relatively narrow recommendations for matrix materials and lack of robust data on analytical and clinical performance. The aim of this study was to go beyond specifications and validate the assay on relevant clinical materials such as BAL/BL and blood, as well as evaluating the efficacy and performance impact of chemical inactivation procedures.

Safety has been a serious concern when handling clinical samples potentially containing SARS- (24, 25) .

Since the beginning of the outbreak, some clinical studies have reported on quantitative and semi-quantitative detection of SARS-CoV-2 RNA in different clinical materials over the course of treatment (7, 8, 26) . However, quantification results that are precise and reproducible across laboratories require highly standardized reference material, which is not yet available.

Vogels et al. recently provided data on performance and linearity for the most commonly used SARS-CoV-2 inhouse assays, demonstrating that linear range and PCR efficiency does vary to a considerable degree (27) . However, other factors such as extraction methods, and choice of enzymes and cyclers will render comparability between sites difficult, even when using the same assays.

In this study we demonstrate that the SARS-CoV-2 IVD dual-target assay is highly efficient and offers a wide linear range in different types of matrix materials outside official specifications.

Based on our data, it seems preferable to use the Target-2 (E gene) CT for quantification purposes as it performed slightly better than Target-1 (ORF1ab) in this trial. Compared to the inhouse assay SARS-CoV-2 UCT, the SARS-CoV-2 IVD assay showed good agreement for a total of 180 respiratory swab samples, which is in line with previously reported data (12) . 

In this study we provide evaluation for different matrix materials and clinical performance of the SARS-CoV-2 IVD for the cobas6800/8800 systems. We observed excellent linearity over four to six log steps in different clinically relevant materials outside assay specifications, including human plasma samples, BAL/BL and swab medium pre-treated for chemical inactivation. Furthermore, deviations in CT values were minimal when identical samples were analyzed at different testing sites. The assay showed excellent correlation with the comparator assay for all specimen types analyzed, indicating compatibility of a variety of clinical materials despite not being officially recommended for use by the manufacturer.

Overall, this data demonstrates the viability of the assay for providing reproducible 

China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Use of laboratory methods for SARS diagnosis. World Health Organisation Website (whoint)

Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR

Initial viral load and the outcomes of SARS

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Quantification of mRNA using real-time RT-PCR

Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system

Clinical evaluation of multiplex RT-PCR assays for the detection of influenza A/B and respiratory syncytial virus using a high throughput system

Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic

Detection of C. difficile toxin as a model assay for performing fully automated highthroughput RT-PCR on clinical stool samples

Complete Genome Sequence of a SARS-CoV-2 Strain Isolated in Northern Germany

Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test

Ten years of R&D and full automation in molecular diagnosis

Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion

Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting

Multicenter evaluation of the NeuMoDx™ SARS-CoV-2 Test

Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2

Heat inactivation of the Middle East respiratory syndrome coronavirus

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads

Evaluation of heating and chemical protocols for inactivating SARS-CoV-2

Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type

Temporal dynamics in viral shedding and transmissibility of COVID-19

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets